Tag
This study highlights dupilumab’s long-term effectiveness and safety in managing pediatric atopic dermatitis over 3 years, revealing age-related differences in symptom control and treatment persistence.
This multicenter study reveals that pruritus affects one in four patients with primary sclerosing cholangitis (PSC), persists over time, and correlates with disease severity, underscoring its clinical significance and guiding future therape
Pooled analysis of the ENHANCE and RESPONSE phase 3 trials shows seladelpar 10 mg reduces pruritus and sleep disturbance in patients with primary biliary cholangitis (PBC) and moderate-to-severe baseline itch versus placebo over 6 months, w
This phase 3 trial demonstrates that anrikefon significantly reduces pruritus intensity and improves quality of life in patients undergoing haemodialysis with moderate to severe chronic kidney disease-associated pruritus, with a favorable s
Peak bile acid levels and higher maternal BMI independently predict pruritus worsening in intrahepatic cholestasis of pregnancy, emphasizing the need for tailored monitoring and management as gestation advances.
CKD-associated pruritus affects up to 85% of dialysis patients and significantly impairs quality of life. Stepwise management, including novel therapies like nemolizumab, is essential for effective symptom control and improved patient outco
